2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6297 Outcomes following autologous stem cell transplantation (ASCT) for patients who are incarcerated

Warren Fingrut, MD, MPH, Olugbenga Ojo2, Roland Bassett3, Ricky Garcia4, Celina Ledesma5, Morgan Straubel6, Lihui Cao7, Catherine Delanoix8, Hilary Sullivan9, Nicole Zhao10, Erin Freeman11, Owen Murray12, Lannette Linthicum13, Maurice Willis14, Sairah Ahmed, MD15, Qaiser Bashir, MD16, Yago Nieto, MD, Ph.D17, Uday Popat, MD, MBA18, Muzaffar Qazilbash, MD19, Jeremy Ramdial, MD20, Samer A Srour, MB ChB, MS21, Chitra Hosing, MD22, Partow Kebriaei, MD23, Christopher R. Flowers Jr, MD, MS24, Richard Champlin25, Elizabeth Shpall, MD26
1 Equal contribution, N/A, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Equal contribution, N/A, United States, Texas Department of Criminal Justice Hospital & Clinics, Galveston, Texas, United States, University of Texas Medical Branch, Galveston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 University of Texas Medical Branch, Galveston, Texas, United States
12 University of Texas Medical Branch, Galveston, Texas, United States
13 Texas Department of Criminal Justice, Huntsville, Texas, United States
14 University of Texas Medical Branch, Galveston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction: Although autologous stem cell transplantation (ASCT) is a critically important therapy for many cancer patients (pts), little data are available to guide ASCT care delivery for pts who are incarcerated.

Methods: Since 2013, MD Anderson (MDACC) has collaborated with Texas Department of Criminal Justice (TDCJ) & University of Texas Medical Branch (UTMB) to care for pts who are incarcerated who need ASCT. We assessed these pts & if eligible for ASCT, admitted for cell collection followed by high dose chemotherapy, ASCT & recovery. Pts were hospitalized for cell collection & ASCT in a single pt room. Safety, security & medical considerations were discussed with TDCJ pre-admission & in real time. In accordance with TDCJ security requirements, appropriate restraint measures were used. TDCJ correctional officers escorted the pts to all outpt visits & were present throughout inpt hospitalizations. UTMB oncologists provided post-ASCT maintenance therapy & care with guidance from MDACC ASCT physicians. Here, we report referral, cell mobilization & ASCT outcomes for these pts. Kaplan-Meier method was used to estimate overall survival (OS) & progression-free survival (PFS) from ASCT date.

Results: From 1/2013-6/2026, 58 pts were evaluated for ASCT [1 twice, for first & second (2nd) ASCT]. Of these, 16 were not transplanted (4 lacked indication; 3 declined; 7 ineligible due to comorbidities &/or disease state; 2 released from prison post-consult). For 3, ASCT evaluation is in process.

39 pts [median age 51 (range 24-68) years (yrs)] were admitted for cell mobilization followed by ASCT. 1 was readmitted 5-yrs later for 2nd ASCT. Nearly all (n=38) were male with 79% Black (n=26) or Hispanic (n=5). Median (range) HCT-CI was 1 (0-5) & KPS 80% (60-90%). 27 had myeloma (11 high risk by FISH/cytogenetics), 10 lymphoma [7 Hodgkins (HL), 2 T-lymphoblastic, 1 mantle cell (MCL)], 1 blastic plasmacytoid dendritic cell neoplasm & 1 germ cell tumor (GCT). The pt with GCT had a tandem ASCT. 2 pts with myeloma had a 2nd ASCT (1 had both during incarceration 5-yrs apart; 1 had ASCT pre-incarceration & 8-yrs later underwent re-mobilization & 2nd ASCT while incarcerated). Prior to ASCT, 25/28 (89%) myeloma pts achieved at least very good partial remission & lymphoma pts achieved complete (n=9) or partial (n=1) response. 

Pts underwent cell mobilization with GCSF; 19 also received plerixafor, 6 ifosfamide/etoposide (E) ± Carboplatin (C), 2 cyclophosphamide & 1 Gemcitabine (Gem)/Oxaliplatin. 2 required 2nd mobilization. Median 7.9 (range 3.4-11.0) CD34+ cells/kg pt body weight were collected over median 2 (range 1-8) apheresis sessions. 

39 pts received 41 ASCT infusions. Most (n=24, 59%) were conditioned with melphalan (mel) 200mg/m2 & 5 each with mel/Busulfan (Bu), BCNU/E/Cytarabine/Mel & Vorinostat/Gem/Bu/Mel. The pt with GCT had Gem/Docetaxel/Mel/C then C/E. Median (range) neutrophil engraftment & platelet recovery (>20K) times were 11 (8-13) & 12 (9-39) days. Median admission duration was 33 (range 22-86) days. 3 pts required ICU transfer for sepsis (1 twice; 1 intubated 6 days). None died during the ASCT hospitalization. 9 were readmitted (6 for infections) within 6 months of ASCT (3 at MDACC; 6 other hospitals) for median 4 (range 2-15) days.

Pts followed up at MDACC for median 1.6 (range 0.1-10.6) yrs. 28 had post-ASCT maintenance therapy [26 myeloma, 1 HL, 1 MCL]. 14 were released from prison at median 1.7 (range 0.3-7.3) yrs post-ASCT; 2 had MDACC follow-up post-release. 

Median follow-up among survivors was 2.4 (range 0.1-9.8) yrs. 11 pts died at median 2.3 (range 0.9-9.4) yrs post ASCT.  Median 1-, 3- & 5-yr OS & 95% confidence intervals (CI) were 97.1% (91.8-100%), 71.1% (55.8-90.6%) & 65.6% (49.2-87.6%). For myeloma, 3-yr OS was 61.6% (95% CI 43.6-87.1%) & 3-yr PFS 59% (95% CI 41.3-84.7%) with median PFS 4.84 yrs. For lymphoma, 5-yr OS was 100% (95% CI 100-100%) & 5-yr PFS 88.9% (95% CI 70.6-100%).

Conclusion: We report the largest series to our knowledge of ASCT during incarceration, including granular data on pt assessment, cell mobilization & outcomes. These data will inform ASCT decision-making & care optimization for this population & will guide centers seeking to establish similar programs in their jurisdictions. 

The research contained in this presentation was coordinated in part by TDCJ (911-RM25). The contents of this presentation reflect the views of the author(s) & do not necessarily reflect the views/policies of TDCJ.

Warren Fingrut, MD, MPH: No relevant conflicts of interest to declare.